Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study

Ramanjot Kaur, Catherine Tchanque-Fossuo, Kaitlyn West, Yasmin Hadian, Anthony Gallegos, Daniel Yoon, Ligia Ismailyan, Saul Schaefer, Sara E Dahle, R Rivkah Isseroff, Ramanjot Kaur, Catherine Tchanque-Fossuo, Kaitlyn West, Yasmin Hadian, Anthony Gallegos, Daniel Yoon, Ligia Ismailyan, Saul Schaefer, Sara E Dahle, R Rivkah Isseroff

Abstract

Background: Diabetic foot ulcers (DFUs) are the most common cause of leg amputations and their management is extremely challenging. Despite many advances and expensive therapies, there has been little success in improving outcomes of DFUs. In prior work our laboratory has examined the effects of beta-adrenergic antagonists (βAAs) on skin and skin-derived cells. We have shown that βAAs enhance the rate of keratinocyte migration, promote angiogenesis, and hasten wound healing in scratch wounds in vitro, in animal wound models, and in anecdotally reported cases of chronic wounds that healed successfully after topical application of the βAA timolol. Thus, we propose to test timolol directly on DFUs to determine if it improves healing above the current standard of care (SOC). This study will examine the efficacy and safety of topically applied beta-antagonist Timoptic-XE® (timolol maleate ophthalmic gel forming solution) in subjects with DFUs.

Methods/design: This is a phase two, randomized, double-blinded, controlled, and parallel-group clinical trial with two treatment arms, SOC plus topical Timoptic-XE® and SOC plus a non-biologically active gel (hydrogel, as placebo drug). Study subjects with a DFU will be selected from the Veterans Affairs Northern California Health Care System (VANCHCS). Study duration is up to 31 weeks, with three phases (screening phase for two weeks, active phase for up to 12 weeks, with an additional second consecutive confirmatory visit after 2 weeks, and follow-up phase comprising monthly visits for 4 months). Subjects will apply daily either the topical study drug or the placebo on the foot ulcer for 12 weeks or until healed, whichever comes first. Measurements of wound size and other data will be collected at baseline, followed by weekly visits for 12 weeks, and then a monthly follow-up period.

Discussion: This is a clinical translation study, moving the investigators' pre-clinical laboratory research into a translational study in which we will analyze clinical outcomes to assess for safety and estimate the efficacy of a topical beta-antagonist in healing of DFUs. The results from this trial may establish new treatment paradigms and safety profile for DFU treatment.

Trial registration: ClinicalTrials.gov, NCT03282981. Registered on June 14th, 2018.

Keywords: Chronic wounds; Diabetic foot ulcer; Nonhealing wounds; Randomized controlled trial; Timolol.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study timeline
Fig. 2
Fig. 2
Study diagram
Fig. 3
Fig. 3
Summary of selection process

References

    1. Meijer JW, Trip J, Jaegers SM, Links TP, Smits AJ, Groothoff JW, et al. Quality of life in patients with diabetic foot ulcers. Disabil Rehabil. 2001;23(8):336–340.
    1. Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2016;2:CD011255.
    1. International W. International Best Practices Guidelines: Wound management in diabetic foot ulcers 2013 [Available from: . Accessed Feb 2020.
    1. Fortington LV, Geertzen JH, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013;46(1):124–131.
    1. Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007;4(4):286–287.
    1. Mayfield JA, Reiber GE, Maynard C, Czerniecki J, Sangeorzan B. The epidemiology of lower-extremity disease in veterans with diabetes. Diabetes Care. 2004;27(Suppl 2):B39–B44.
    1. Reiber GE, Koepsell TD, Maynard C, Haas LB, Boyko EJ. Diabetes in nonveterans, veterans, and veterans receiving Department of Veterans Affairs health care. Diabetes Care. 2004;27(Suppl 2):B3–B9.
    1. Association TAD. 2016 [Available from: . Accessed Feb 2020.
    1. National Center for Veterans Analysis and Statistics [Internet]. 2016. Available from: . Accessed Feb 2020.
    1. Dubois W. Not your granddaddy’s VA - Changing diabetes care for veterans: Healthline; 2012 [Available from: . Accessed Feb 2020.
    1. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care. 1999;22(7):1036–1042.
    1. Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab. 2018;9(1):29–31.
    1. Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu ZR. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev. 2012;28(Suppl 1):107–111.
    1. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008;24(Suppl 1):S3–S6.
    1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217–228.
    1. Vuorisalo S, Venermo M, Lepantalo M. Treatment of diabetic foot ulcers. J Cardiovasc Surg. 2009;50(3):275–291.
    1. de Groot AC, van Ginkel CJ, Bruynzeel DP, Smeenk G, Conemans JM. Contact allergy to eyedrops containing beta-blockers. Ned Tijdschr Geneeskd. 1998;142(18):1034–1036.
    1. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care. 2002;25(10):1835–1839.
    1. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2003;26(6):1696–1700.
    1. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Investig Dermatol Symp Proc. 1997;2(1):37–40.
    1. Steinkraus V, Steinfath M, Korner C, Mensing H. Binding of beta-adrenergic receptors in human skin. J Invest Dermatol. 1992;98(4):475–480.
    1. Steinkraus V, Mak JC, Pichlmeier U, Mensing H, Ring J, Barnes PJ. Autoradiographic mapping of beta-adrenoceptors in human skin. Arch Dermatol Res. 1996;288(9):549–553.
    1. Chen J, Hoffman BB, Isseroff RR. Beta-adrenergic receptor activation inhibits keratinocyte migration via a cyclic adenosine monophosphate-independent mechanism. J Invest Dermatol. 2002;119(6):1261–1268.
    1. Sivamani RK, Pullar CE, Manabat-Hidalgo CG, Rocke DM, Carlsen RC, Greenhalgh DG, et al. Stress-mediated increases in systemic and local epinephrine impair skin wound healing: potential new indication for beta blockers. PLoS Med. 2009;6(1):e12.
    1. Dasu MR, Ramirez SR, La TD, Gorouhi F, Nguyen C, Lin BR, et al. Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healing. Stem Cells Transl Med. 2014;3(6):745–759.
    1. Pullar CE, Le Provost GS, O'Leary AP, Evans SE, Baier BS, Isseroff RR. beta2AR antagonists and beta2AR gene deletion both promote skin wound repair processes. J Invest Dermatol. 2012;132(8):2076–2084.
    1. Pullar CE, Manabat-Hidalgo CG, Bolaji RS, Isseroff RR. beta-Adrenergic receptor modulation of wound repair. Pharmacol Res. 2008;58(2):158–164.
    1. Sivamani RK, Shi B, Griffiths E, Vu SM, Lev-Tov HA, Dahle S, et al. Acute wounding alters the beta2-adrenergic signaling and catecholamine synthetic pathways in keratinocytes. J Invest Dermatol. 2014;134(8):2258–2266.
    1. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453(7193):314–321.
    1. Pullar CE, Grahn JC, Liu W, Isseroff RR. Beta2-adrenergic receptor activation delays wound healing. FASEB J. 2006;20(1):76–86.
    1. Pullar CE, Rizzo A, Isseroff RR. beta-Adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. J Biol Chem. 2006;281(30):21225–21235.
    1. Sivamani RK, Lam ST, Isseroff RR. Beta adrenergic receptors in keratinocytes. Dermatol Clin. 2007;25(4):643–653.
    1. Raja, Sivamani K, Garcia MS, Isseroff RR. Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci. 2007;12:2849–2868.
    1. Ghoghawala SY, Mannis MJ, Pullar CE, Rosenblatt MI, Isseroff RR. Beta2-adrenergic receptor signaling mediates corneal epithelial wound repair. Invest Ophthalmol Vis Sci. 2008;49(5):1857–1863.
    1. Pullar CE, Isseroff RR. Beta 2-adrenergic receptor activation delays dermal fibroblast-mediated contraction of collagen gels via a cAMP-dependent mechanism. Wound Repair Regen. 2005;13(4):405–411.
    1. Lindenschmidt RC, Witschi HP. Propranolol-induced elevation of pulmonary collagen. J Pharmacol Exp Ther. 1985;232(2):346–350.
    1. Gulcan E, Kucuk A, Cayci K, Tosun M, Emre H, Koral L, et al. Topical effects of nebivolol on wounds in diabetic rats. Eur J Pharm Sci. 2012;47(2):451–455.
    1. Lev-Tov H, Dahle S, Moss J, Isseroff RR. Successful treatment of a chronic venous leg ulcer using a topical beta-blocker. J Am Acad Dermatol. 2013;69(4):e204–e205.
    1. Binkley JM, Stratford PW, Lott SA, Riddle DL. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. Phys Ther. 1999;79(4):371–383.
    1. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a pratical and powerful approach to mulitple testing. JR Stat Soc Series B Stat Methodol. 1995;57:289–300.
    1. Merck Sharp & Dohme Research Laboratories. TIMOPTIC® (timolol maleate) [package insert]. 2005. . Accessed Feb 2020.
    1. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–1742.
    1. Zimmerman TJ, Kaufman HE. Timolol, dose response and duration of action. Arch Ophthalmol. 1977;95(4):605–607.
    1. Uusitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol. 1989;67(5):573–581.
    1. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol. 2010;146(5):564–565.
    1. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol. 2011;129(3):377–379.
    1. Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology. 2011;223(4):330–334.
    1. Moehrle M, Leaute-Labreze C, Schmidt V, Rocken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol. 2013;30(2):245–249.
    1. Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara-Corrales I, Lam J, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28–31.
    1. Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthalmic Plast Reconstr Surg. 2012;28(2):103–106.
    1. Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol. 2013;38(2):143–146.
    1. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739–e1747.
    1. Admani S, Feldstein S, Gonzalez EM, Friedlander SF. Beta blockers: an innovation in the treatment of infantile hemangiomas. J Clin Aesthet Dermatol. 2014;7(7):37–45.
    1. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736–1743.
    1. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013;131(1):99–108.
    1. Randomization. 2007. . Accessed Feb 2020.
    1. Vlasses PH, Ribeiro LG, Rotmensch HH, Bondi JV, Loper AE, Hichens M, et al. Initial evaluation of transdermal timolol: serum concentrations and beta-blockade. J Cardiovasc Pharmacol. 1985;7(2):245–250.
    1. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240(6):430–435.
    1. Brooks M. FDA Oks Propanolol hydrochloride for infantile hemangioma 2014 [Available from: . Accessed Feb 2020.
    1. Tang JC, Dosal J, Kirsner RS. Topical timolol for a refractory wound. Dermatol Surg. 2012;38(1):135–138.
    1. Manahan MN, Peters P, Scuderi S, Surjana D, Beardmore GL. Topical timolol for a chronic ulcer--a case with its own control. Med J Aust. 2014;200(1):49–50.
    1. Gallegos AC, Davis MJ, Tchanque-Fossuo CN, West K, Eisentrout-Melton A, Peavy TR, et al. Absorption and safety of topically applied timolol for treatment of chronic cutaneous wounds. Adv Wound Care (New Rochelle) 2019;8(11):538–545.
    1. FDA. What is a Serious Adverse Event? Food and Drugs. . Accessed Feb 2020. Revised February 1, 2016.
    1. Chin RL, B. Priniciples and practice of clinical trial medicine London. England: Academic press; 2008.
    1. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885–910.
    1. Braun LR, Lamel SA, Richmond NA, Kirsner RS. Topical timolol for recalcitrant wounds. JAMA Dermatol. 2013;149(12):1400–1402.
    1. STPLAN: Double precision study planning calculations [Internet]. 2010 [cited 2019]. Available from: .
    1. Padgett DA, Marucha PT, Sheridan JF. Restraint stress slows cutaneous wound healing in mice. Brain Behav Immun. 1998;12(1):64–73.
    1. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995;346(8984):1194–1196.
    1. Schallreuter KU, Wood JM, Lemke R, LePoole C, Das P, Westerhof W, et al. Production of catecholamines in the human epidermis. Biochem Biophys Res Commun. 1992;189(1):72–78.
    1. Pullar CE, Zhao M, Song B, Pu J, Reid B, Ghoghawala S, et al. Beta-adrenergic receptor agonists delay while antagonists accelerate epithelial wound healing: evidence of an endogenous adrenergic network within the corneal epithelium. J Cell Physiol. 2007;211(1):261–272.
    1. Kim MH, Gorouhi F, Ramirez S, Granick JL, Byrne BA, Soulika AM, et al. Catecholamine stress alters neutrophil trafficking and impairs wound healing by beta2-adrenergic receptor-mediated upregulation of IL-6. J Invest Dermatol. 2014;134(3):809–817.
    1. Bell-Syer SE, Foxlee RE, Cullum NA. The Cochrane Wounds Group: systematically reviewing the wound care literature. Adv Skin Wound Care. 2007;20(5):283–287.
    1. US general population male/female census [Internet]. 2018. Available from: . Accessed Feb 2020.
    1. Veteran Health System. 2016 [Internet]. [cited 2019]. Available from: .
    1. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219–1222.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅